Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.63 |
| ▸ | HRH1 | P35367 | 2/20 | 0.62 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886790 | 0.95 | KDM4E (0.59) | KDM4EALDH1A1SMN1; SMN2HRH3HRH1 | |
| SCHEMBL6945688 | 0.92 | LTA4H (0.61) | KDM4EALDH1A1SMN1; SMN2HRH3TMEM97 | |
| SCHEMBL8114904 | 0.92 | LTA4H (0.61) | KDM4EALDH1A1SMN1; SMN2HRH3TMEM97 | |
| SCHEMBL7033807 | 0.86 | HTR1A (0.80) | KDM4EALDH1A1SMN1; SMN2HRH3HRH1 | |
| SCHEMBL492205 | 0.82 | HRH3 (0.84) | KDM4EALDH1A1SMN1; SMN2HRH3HRH1 | |
| SCHEMBL5635479 | 0.82 | NPC1 (0.55) | TMEM97SIGMAR1HTR1ADRD2KCNH2 | |
| Hydrochloric Acid SCHEMBL27860615 | 0.81 | HTR1A (0.73) | KDM4EALDH1A1SMN1; SMN2HRH3HRH1 | |
| SCHEMBL2823877 | 0.81 | HRH3 (0.87) | KDM4EALDH1A1SMN1; SMN2HRH3HRH1 | |
| SCHEMBL4084100 | 0.81 | HRH3 (0.87) | KDM4EALDH1A1SMN1; SMN2HRH3HRH1 | |
| SCHEMBL6655573 | 0.80 | KMT2A (0.60) | KDM4EALDH1A1HRH3DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397616-B1 | LSD1 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3397616-B1 | LSD1 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-10233152-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3397616-A1 | LSD1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| US-20180127369-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. | 2018-05-10 | — | — | US | disclosed |
| US-9809541-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809541-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2017-11-07 | — | — | US | disclosed |
| WO-2017116558-A1 | LSD1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017116558-A1 | LSD1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170183308-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. (US) | 2017-06-29 | — | — | US | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| US-6124323-A | ACTIVE DRUG TREATING STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMIOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE HEADACHES, CHRONIC PAIN, GLAUCOMA, CMV RETINITIS, PSYCHOSIS | WARNER-LAMBERT COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0869792-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| EP-0869792-A2 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5760035-A | PIPERIDINE COMPOUNDS SUBSTITUTED WITH AN AMINOALKYL GROUP AND AN ARYLOXYALKYL GROUP, ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, IMMUNOSUPPRESSANTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-06-02 | — | — | US | disclosed |
| EP-0720602-B1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1997-07-09 | — | — | EP | disclosed |
| WO-1997023216-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
| EP-0720602-A1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995008535-A1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233152-B2 | LSD1 inhibitors | KDM1B, KDM1A, KDM3A | KDM4E 14/4885ALDH1A1 364/4885SMN1; SMN2 3266/4885 |
| US-20170183308-A1 | LSD1 Inhibitors | KDM1B, KDM1A, KDM3A | KDM4E 14/4885ALDH1A1 364/4885SMN1; SMN2 3266/4885 |
| US-20180127369-A1 | LSD1 Inhibitors | KDM1B, KDM1A, KDM3A | KDM4E 14/4885ALDH1A1 364/4885SMN1; SMN2 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.